ReviewMalaria journal2021
Anti-malarial drug effects on parasite dynamics in vivax malaria.
Review in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Pooled it
- Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.Malaria journal · 2024Trial
- Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.The Lancet. Infectious diseases · 2022Trial
- Pharmacokinetics of chloroquine and primaquine in healthy volunteers.Malaria journal · 2022Trial
- UnderstandingiScience · 2026Article
- Article
- Travel-Related Malaria Diagnosis on Karius Test Despite Negative Blood Smear.Tropical medicine and infectious disease · 2025Article
- Modeling the within-host dynamics ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Correlative light-electron microscopy methods to characterize the ultrastructural features of the replicative and dormant liver stages of Plasmodium parasites.Malaria journal · 2024Article
- Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review.Infectious diseases and therapy · 2023Review
- Article
- The assessment of antimalarial drug efficacy in vivo.Trends in parasitology · 2022Review
- Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials.British journal of clinical pharmacology · 2022Review
- Decoquinate liposomes: highly effective clearance of Plasmodium parasites causing severe malaria.Malaria journal · 2022Article
- Review
- Studies of Potency and Efficacy of an Optimized Artemisinin-Quinoline Hybrid against Multiple Stages of thePharmaceuticals (Basel, Switzerland) · 2021Article
- The prevention and treatment of Plasmodium vivax malaria.PLoS medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
Relapses of Plasmodium vivax malaria are prevented by 8-aminoquinolines. If hypnozoites survive, then the subsequent blood stage infections in early relapses (< 2 months) are suppressed by the slowly eliminated anti-malarial drugs used to treat the blood stage infection (chloroquine, artemisinin combination treatments), but they are not usually eliminated. The 8-aminoquinolines have significant blood stage activity which contributes to therapeutic responses. The latent interval from primary infection to early relapse depends on the number of activatable hypnozoites, the dose of anti-malarial, its pharmacokinetic properties, the level of resistance (minimum inhibitory concentration) and immunity. The dose-response relationship for radical curative efficacy of primaquine and tafenoquine is steep over the total dose range from 1.5 to 5 mg base/kg which may explain the poor efficacy of tafenoquine at the currently recommended dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.